ArticleDermatology and therapy2022

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.

Jeffrey J Crowley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.